

Our Mission:

The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure.

Results to Date:

- Ten new drugs approved by the FDA in the past 10 years
- Opened a record-breaking 10 clinical trials in 2014
- 69 MMRC clinical trials launched
- Over 1,000 patients enrolled in the MMRF Compass Study
- Nearly tripled life expectancy for patients
- First to sequence the myeloma genome
- Over 350 research grants funded

About Multiple Myeloma

Multiple myeloma is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 30,330 adults (17,900 men and 12,430 women) in the United States will be diagnosed with multiple myeloma in 2016 and an estimated 12,650 people (6,430 men and 6,220 women) are predicted to die from the disease.

About the Multiple Myeloma Research Foundation (MMRF) The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c) (3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised more than \$300 million since its inception and directs nearly 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator's coveted four-star rating for 11 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency.

Learn more about the MMRF by visiting: www.themmr.org